RecruitingNot ApplicableNCT06409169

DBS TaT in Peer-assisted Telemedicine for Hepatitis C

Dried Blood Spot Testing in Peer-assisted Telemedicine for Hepatitis C Treatment

Sponsor

Oregon Health and Science University

Enrollment

141 participants

Start Date

Jan 22, 2025

Study Type

INTERVENTIONAL

Conditions

Hepatitis C

Summary

The purpose of this study is to compare the rate of treatment initiation achieved by peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a new protocol, called Dried Blood Spot Test and Treat (DBS TaT). DBS TaT includes DBS testing to diagnose hepatitis C (HCV), utilizes a novel clinical decision aid that identifies patients who are low risk for hepatic (liver) fibrosis, and directs those patients to HCV treatment initiation prior to routine hepatic fibrosis assessment. The investigators hypothesize that DBS TaT will increase the rate of HCV treatment initiation compared to peer-assisted telemedicine contingent on phlebotomy (usual care).

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Active hepatitis C infection
Willing to engaged with the PATHS program for clinical care

Exclusion Criteria1

• Currently pregnant

Interventions

OTHERDBS TaT

Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)

OTHERUsual Care

Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)